公开(公告)号：US12012462B2

公开(公告)日：2024-06-18

申请号：US17046731

申请日：2019-04-10

申请人： AMGEN INC. ,  KiTe Pharma, Inc.

发明人： Michael John Giffin ,  Melissa Thomas ,  Christopher Murawsky ,  Ryan B. Case ,  Lawren Wu ,  Jed J. Wiltzius ,  Ruben Alvarez Rodriguez ,  Jun Feng

IPC分类号： C07K16/30 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C12N15/86

CPC分类号： C07K16/30 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70521 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/565 ,  C07K2317/622 ,  C12N2740/15041

摘要： Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.

公开(公告)号：US10597456B2

公开(公告)日：2020-03-24

申请号：US15476699

申请日：2017-03-31

申请人： KITE PHARMA, Inc. ,  AMGEN INC.

发明人： Jed Wiltzius ,  Ruben Alvarez Rodriguez ,  Alice Bakker ,  Lawren Wu ,  Tara Arvedson

IPC分类号： C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00 ,  C07K14/435 ,  C12N15/86

摘要： Antigen binding molecules, chimeric receptors, and engineered immune cells are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the antigen binding molecules and engineered immune cells.

公开(公告)号：US10689450B2

公开(公告)日：2020-06-23

申请号：US15476309

申请日：2017-03-31

申请人： KITE PHARMA, INC.

发明人： Jed Wiltzius ,  Ruben Alvarez Rodriguez ,  Jonathan Belk

IPC分类号： C07K16/28 ,  C07K14/705 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/7088 ,  A61P35/02 ,  A61P35/00 ,  A61K45/06 ,  A61K35/00

摘要： The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

公开(公告)号：US20200246382A1

公开(公告)日：2020-08-06

申请号：US16711180

申请日：2019-12-11

申请人： Kite Pharma, Inc.

发明人： Arianne Perez ,  Stuart A. Sievers ,  Ruben Alvarez Rodriguez ,  Jonathan Belk

IPC分类号： A61K35/17 ,  C07K16/28 ,  A61P35/00

摘要： Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

公开(公告)号：US20240115611A1

公开(公告)日：2024-04-11

申请号：US18470745

申请日：2023-09-20

申请人： Kite Pharma, Inc.

发明人： Arianne Perez ,  Stuart A. Sievers ,  Ruben Alvarez Rodriguez ,  Jonathan Belk ,  Jed Wiltzius

IPC分类号： A61K35/17 ,  A61P35/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/63

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N5/10 ,  C12N15/63 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76

摘要： Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

公开(公告)号：US11793834B2

公开(公告)日：2023-10-24

申请号：US16711180

申请日：2019-12-11

申请人： Kite Pharma, Inc.

发明人： Arianne Perez ,  Stuart A. Sievers ,  Ruben Alvarez Rodriguez ,  Jonathan Belk ,  Jed Wiltzius

IPC分类号： C07K16/28 ,  C12N5/10 ,  C12N15/63 ,  A61K35/17 ,  A61P35/00

CPC分类号： A61K35/17 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N5/10 ,  C12N15/63 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76

摘要： Provided is a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs disclosed herein. Aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) or a T cell receptor (TCR) comprising one or more of the antigen binding motifs. Provided are antibodies and antigen binding systems that comprise a binding motif that binds CD20 and optionally a binding motif that binds CD19, and methods of producing and using the same. Antibodies and antigen binding systems of the present disclosure comprise CARs that comprise an anti-CD20 binding motif and an anti-CD19 binding motif. Provided are compositions, such as antibodies and CARs that are or comprise an anti-CD20/anti-CD19 antigen binding system of the present disclosure, and cell therapies comprising the same, are useful, e.g., in the treatment of cancer.

公开(公告)号：US11505613B2

公开(公告)日：2022-11-22

申请号：US16569341

申请日：2019-09-12

申请人： KITE PHARMA, INC.

发明人： Jed Wiltzius ,  Ruben Alvarez Rodriguez ,  Jonathan Belk

IPC分类号： C07K16/28 ,  C07K14/705 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/7088 ,  A61P35/00 ,  A61P35/02 ,  A61K45/06 ,  A61K35/00

摘要： The invention provides antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

公开(公告)号：US11046775B2

公开(公告)日：2021-06-29

申请号：US15896619

申请日：2018-02-14

申请人： KITE PHARMA, INC.

发明人： Ruben Alvarez Rodriguez ,  Armen Mardiros

IPC分类号： C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783 ,  A61P35/00

摘要： The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.